Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LA JOLLA PHARMACEUTICAL COLJPC · Entity 124310 | Chief Scientific Officer | May 29, 2020 | June 02, 2020 |
| REVELATION BIOSCIENCES, INC.REVB · Entity 8359 | Director · Chief Executive Officer | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LA JOLLA PHARMACEUTICAL CO
Report date May 29, 2020 · Filed June 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,771 |
Reported balance
After 2020-05-29 transaction · row 1
1 source rowRow 1 · 2020-05-29 · Grant · Acquired 205 · Balance 81,771 F1: These shares were acquired on 05/29/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2030-05-29 | Direct | 205 |
Reported balance
After 2020-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-29 · Grant · Acquired 205 · Balance 205 F2: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired on 05/29/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.
REVELATION BIOSCIENCES, INC.
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 422,814 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 208,076 · Balance 422,814 F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 21:00 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 208,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355663 · ownership.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,814 F1 · shares: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. Read SEC document |
| April 30, 2026 Filed May 1, 2026 21:32 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | Tax withholdingCommon Stock | 10,115 | $1.13 | $11,429.95 |
DisclosureSEC source: 0001193125-26-201769 · ownership.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,738 F1 · shares: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.14, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 22:29 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | Tax withholdingCommon Stock | 8,521 | $1.86 | $15,849.06 |
DisclosureSEC source: 0001193125-26-039690 · ownership.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,853 F1 · shares: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. F2 · shares: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:21 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 532,829 | $0.90 | $479,546.10 |
DisclosureSEC source: 0001193125-26-010648 · ownership.xml · nonDerivative · entry 2 Rolke James · CIK 0001693858 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 933,489 F1 · security: Restricted Stock Units under the 2021 Equity Incentive Plan. Vests quarterly over two years from the date of grant. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 16:58 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 390,614 | $1.28 | $499,985.92 |
DisclosureSEC source: 0001193125-25-260423 · ownership.xml · nonDerivative · entry 2 Rolke James · CIK 0001693858 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,660 F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests quarterly over one year from the grant date. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 23:07 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 30,095 | $3.87 | $116,467.65 |
DisclosureSEC source: 0000950170-25-020109 · ownership.xml · nonDerivative · entry 2 Rolke James · CIK 0001693858 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,137 F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 21:08 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantStock Option (Right to Buy) · Derivative | 2,542 | $0.00 Strike: $49.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013629 · doc4.xml · derivative · entry 1 Rolke James · CIK 0001693858 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,542 shares Expires 2032-02-25 F1 · derivative.exercise_date: The stock options were granted on 2/25/2022 and vest 25% on the one-year anniversary of the grant date, and thereafter quarterly over a three-year period, subject to continued service through each such vesting date. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 205 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0000920465-20-000081 · wf-form4_159112812263735.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205 Underlying: Common Stock · 205 shares Expires 2030-05-29 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 205 | $4.01 | $822.05 |
DisclosureSEC source: 0000920465-20-000081 · wf-form4_159112812263735.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,771 F1 · kind: These shares were acquired on 05/29/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 15, 2020 Filed May 19, 2020 16:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 140 | $0.00 Strike: $6.89 | $0.00 |
DisclosureSEC source: 0000920465-20-000074 · wf-form4_158991869760750.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 Underlying: Common Stock · 140 shares Expires 2030-05-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| May 15, 2020 Filed May 19, 2020 16:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 140 | $5.86 | $820.40 |
DisclosureSEC source: 0000920465-20-000074 · wf-form4_158991869760750.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,566 F1 · kind: These shares were acquired on 05/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 30, 2020 Filed May 4, 2020 16:09 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 133 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0000920465-20-000065 · wf-form4_158862295345946.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133 Underlying: Common Stock · 133 shares Expires 2030-04-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| April 30, 2020 Filed May 4, 2020 16:09 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 133 | $6.17 | $820.61 |
DisclosureSEC source: 0000920465-20-000065 · wf-form4_158862295345946.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,426 F1 · kind: These shares were acquired on 04/30/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 146 | $0.00 Strike: $6.60 | $0.00 |
DisclosureSEC source: 0000920465-20-000048 · wf-form4_158715372853613.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146 Underlying: Common Stock · 146 shares Expires 2030-04-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 146 | $5.61 | $819.06 |
DisclosureSEC source: 0000920465-20-000048 · wf-form4_158715372853613.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,293 F1 · kind: These shares were acquired on 04/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 18:08 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 229 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0000920465-20-000045 · wf-form4_158586527563021.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229 Underlying: Common Stock · 229 shares Expires 2030-03-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 18:08 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 229 | $3.57 | $817.53 |
DisclosureSEC source: 0000920465-20-000045 · wf-form4_158586527563021.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,147 F1 · kind: These shares were acquired on 03/31/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 16:13 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 241 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0000920465-20-000044 · wf-form4_158438958484301.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241 Underlying: Common Stock · 241 shares Expires 2030-03-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 16:13 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 241 | $3.40 | $819.40 |
DisclosureSEC source: 0000920465-20-000044 · wf-form4_158438958484301.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,918 F1 · kind: These shares were acquired on 03/13/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 16:14 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 142 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0000920465-20-000039 · wf-form4_158327004839858.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142 Underlying: Common Stock · 142 shares Expires 2030-02-28 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 16:14 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 142 | $5.78 | $820.76 |
DisclosureSEC source: 0000920465-20-000039 · wf-form4_158327004839858.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,677 F1 · kind: These shares were acquired on 02/28/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 16:47 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 115 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0000920465-20-000032 · wf-form4_158214884842276.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115 Underlying: Common Stock · 115 shares Expires 2030-02-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 16:47 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 115 | $7.14 | $821.10 |
DisclosureSEC source: 0000920465-20-000032 · wf-form4_158214884842276.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,535 F1 · kind: These shares were acquired on 02/14/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 16:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 141 | $0.00 Strike: $6.85 | $0.00 |
DisclosureSEC source: 0000920465-20-000026 · wf-form4_158085009773446.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141 Underlying: Common Stock · 141 shares Expires 2030-01-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 16:01 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 141 | $5.82 | $820.62 |
DisclosureSEC source: 0000920465-20-000026 · wf-form4_158085009773446.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,420 F1 · kind: These shares were acquired on 01/31/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 16:13 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 692 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0000920465-20-000022 · wf-form4_157929561101622.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 692 Underlying: Common Stock · 692 shares Expires 2030-01-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 16:13 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 692 | $6.70 | $4,636.40 |
DisclosureSEC source: 0000920465-20-000022 · wf-form4_157929561101622.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,279 F1 · kind: These shares were acquired on 01/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 16:19 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0000920465-20-000016 · wf-form4_157895032327136.xml · derivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-01-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 16:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 118 | $0.00 Strike: $6.02 | $0.00 |
DisclosureSEC source: 0000920465-19-000164 · wf-form4_157419794186274.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118 Underlying: Common Stock · 118 shares Expires 2029-11-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 16:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 118 | $5.12 | $604.16 |
DisclosureSEC source: 0000920465-19-000164 · wf-form4_157419794186274.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,587 F1 · kind: These shares were acquired on 11/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 31, 2019 Filed Nov 5, 2019 16:06 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 133 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0000920465-19-000153 · wf-form4_157298795551801.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133 Underlying: Common Stock · 133 shares Expires 2029-10-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 31, 2019 Filed Nov 5, 2019 16:06 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 133 | $5.96 | $792.68 |
DisclosureSEC source: 0000920465-19-000153 · wf-form4_157298795551801.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,469 F1 · kind: These shares were acquired on 10/31/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 17:40 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 112 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0000920465-19-000142 · wf-form4_157134838523013.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112 Underlying: Common Stock · 112 shares Expires 2029-10-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 17:40 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 112 | $7.12 | $797.44 |
DisclosureSEC source: 0000920465-19-000142 · wf-form4_157134838523013.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,336 F1 · kind: These shares were acquired on 10/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 17:06 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 107 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0000920465-19-000137 · wf-form4_157005035002871.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107 Underlying: Common Stock · 107 shares Expires 2029-09-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 17:06 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 107 | $7.48 | $800.36 |
DisclosureSEC source: 0000920465-19-000137 · wf-form4_157005035002871.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,224 F1 · kind: These shares were acquired on 09/30/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 13, 2019 Filed Sep 16, 2019 19:24 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 85 | $0.00 Strike: $10.92 | $0.00 |
DisclosureSEC source: 0000920465-19-000129 · wf-form4_156867627380306.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85 Underlying: Common Stock · 85 shares Expires 2029-09-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| September 13, 2019 Filed Sep 16, 2019 19:24 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 85 | $9.28 | $788.80 |
DisclosureSEC source: 0000920465-19-000129 · wf-form4_156867627380306.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,117 F1 · kind: These shares were acquired on 09/13/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 16:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 98 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0000920465-19-000118 · wf-form4_156754150479713.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98 Underlying: Common Stock · 98 shares Expires 2029-08-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 16:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 98 | $8.13 | $796.74 |
DisclosureSEC source: 0000920465-19-000118 · wf-form4_156754150479713.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,032 F1 · kind: These shares were acquired on 08/30/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 16:51 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 99 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0000920465-19-000112 · wf-form4_156598866484777.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99 Underlying: Common Stock · 99 shares Expires 2029-08-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 16:51 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 99 | $8.02 | $793.98 |
DisclosureSEC source: 0000920465-19-000112 · wf-form4_156598866484777.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,934 F1 · kind: These shares were acquired on 08/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:59 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 112 | $0.00 Strike: $8.36 | $0.00 |
DisclosureSEC source: 0000920465-19-000102 · wf-form4_156477951762022.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112 Underlying: Common Stock · 112 shares Expires 2029-07-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:59 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 112 | $7.11 | $796.32 |
DisclosureSEC source: 0000920465-19-000102 · wf-form4_156477951762022.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,835 F1 · kind: These shares were acquired on 07/31/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 17:10 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 102 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0000920465-19-000096 · wf-form4_156339781200245.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102 Underlying: Common Stock · 102 shares Expires 2029-07-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 17:10 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 102 | $7.85 | $800.70 |
DisclosureSEC source: 0000920465-19-000096 · wf-form4_156339781200245.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,723 F1 · kind: These shares were acquired on 07/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 18:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 101 | $0.00 Strike: $9.25 | $0.00 |
DisclosureSEC source: 0000920465-19-000093 · wf-form4_156201909175001.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101 Underlying: Common Stock · 101 shares Expires 2029-06-28 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 18:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 101 | $7.86 | $793.86 |
DisclosureSEC source: 0000920465-19-000093 · wf-form4_156201909175001.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,621 F1 · kind: These shares were acquired on 06/28/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 16:44 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 96 | $0.00 Strike: $9.71 | $0.00 |
DisclosureSEC source: 0000920465-19-000088 · wf-form4_156089065536215.xml · derivative · entry 2 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96 Underlying: Common Stock · 96 shares Expires 2029-06-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 16:44 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 96 | $8.25 | $792.00 |
DisclosureSEC source: 0000920465-19-000088 · wf-form4_156089065536215.xml · nonDerivative · entry 1 Rolke James · CIK 0001693858 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,520 F1 · kind: These shares were acquired on 06/14/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.